Matuzumab Completed Phase 2 Trials for Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00111839Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer